Lundbeck aims for further growth after record year

Danish drug group Lundbeck rejects market rumors of a quiet fourth quarter of a record year. And the company plans for more growth in 2018 generated by China and a European turnaround.

Photo: /ritzau/Jeppe Bøje Nielsen

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us for 14 days

Try a trial subscription for access to our quality journalism

Related articles